Juventas Cell Therapy Ltd.
PrivateLast Round
Series C
Oct 25, 2021
Est. Valuation
$263.04M
Total Funding Raised
$232.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Juventas Cell Therapy Ltd. is a biotechnology company that develops and manufactures innovative immune cell and gene therapies for the treatment of hematological malignancies and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Juventas Cell Therapy Ltd. Comparables
Compare Juventas Cell Therapy Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hrain Biotechnology Co., Ltd. | 88% | |
| Imunopharm Technology Co., Ltd. | 87% | |
| Shanghai Unicar-Therapy Bio-medicine Technology | 86% |
Juventas Cell Therapy Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 25, 2021 | ||||
| Series C | Jul 12, 2021 | ||||
| Series B | Nov 19, 2020 | ||||
| Series A Extension | Jul 9, 2019 | ||||
| Series A | Dec 17, 2018 |
Juventas Cell Therapy Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Emerging Technology Partners | Series B |
| CCIC Capital | Series C |
| China International Capital Corporation | Series C |
| Dalton Venture | Series A, Series A Extension |
| Tianjin Venture Capital Management Co., Ltd. | Series C, Series B |
| Oceanpine Capital | Series C |
| Delian Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 65% MoM, reaching 2.7K.
- Oct 25, 2021
$63M round led by CCIC Capital and Oceanpine Capital.
Juventas Cell Therapy Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Juventas Cell Therapy Ltd.'s valuation, stock price, and market status.
Is Heyuan Biotechnology a public or private company?
Heyuan Biotechnology is a private company.
What is the current stock price of Heyuan Biotechnology?
Heyuan Biotechnology is a private company with no public stock price. No recent secondary market data is available.
How much is Heyuan Biotechnology worth (valuation)?
Valuation information for Heyuan Biotechnology is not publicly available.
Can I buy Heyuan Biotechnology stock?
Heyuan Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Heyuan Biotechnology's last funding round?
Heyuan Biotechnology's most recent funding round was Series C on July 12, 2021.
Who are the main investors in Heyuan Biotechnology?
Key investors in Heyuan Biotechnology include China International Capital Corporation, Danlu Capital.
Will Heyuan Biotechnology IPO soon?
No public IPO plans have been announced for Heyuan Biotechnology.
How can I track Heyuan Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Heyuan Biotechnology's secondary market activity and sign up for updates.